The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

李耀泰、陳福民、沈仁達、郭宗正（2016）。The role of mTOR inhibitors for endometrial cancer。婦癌醫學期刊，(43)，9-13。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-201604-201605050012-201605050012-9-13
Bunting, K. D., Qu, C. K., & Tomasson, M. H. (2012). Molecular-Targeted Therapies for Hematologic Malignancies. Advances in Hematology, 2012(), 419-420. https://doi.org/10.1155/2012/606423
Bjørn, M. E., & Hasselbalch, H. C. (2015). The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation, 2015(), 465-475-346. https://doi.org/10.1155/2015/648090
Kutsch, N., Marks, R., Ratei, R., Held, T. K., & Hieber, M. S. (2015). Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. Biomarker Insights, 2015(S3), 15-23. https://doi.org/10.4137/BMI.S22434
Reungwetwattana, T., Jaramillo, S., & Molina, J. R. (2011). Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate. Clinical Medicine Insights: Therapeutics, 2011(), 125-135. https://doi.org/10.4137/CMT.S3778